Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma By Ogkologos - August 27, 2026 140 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMBI-I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... January 27, 2020 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 NCI and FDA Address Common Concerns: A Win–Win for Making Progress... September 17, 2018 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 Load more HOT NEWS Immunotherapy for Breast Cancer Treatment: Is It an Option? What Is Peripheral Neuropathy and How Can It Be Prevented or... Opioid Use Drops Among Cancer Patients at End of Life Preoperative ctDNA Levels Are Detectable in the Majority of Patients with...
